Should I buy or sell Dyne Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares. View DYN analyst ratings or view top-rated stocks .

What is Dyne Therapeutics' stock price target for 2024?

5 equities research analysts have issued 1 year price objectives for Dyne Therapeutics' shares. Their DYN share price targets range from $20.00 to $34.00. On average, they predict the company's share price to reach $27.20 in the next twelve months. This suggests a possible upside of 142.9% from the stock's current price. View analysts price targets for DYN or view top-rated stocks among Wall Street analysts .

How have DYN shares performed in 2023?

Dyne Therapeutics' stock was trading at $11.59 on January 1st, 2023. Since then, DYN stock has decreased by 3.4% and is now trading at $11.20. View the best growth stocks for 2023 here .

When is Dyne Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024. View our DYN earnings forecast .

How were Dyne Therapeutics' earnings last quarter?

Dyne Therapeutics, Inc. (NYSE:DYN) announced its quarterly earnings results on Monday, October, 30th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.83) by $0.16.

What ETFs hold Dyne Therapeutics' stock?

ETFs with the largest weight of Dyne Therapeutics (NYSE:DYN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What other stocks do shareholders of Dyne Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dyne Therapeutics investors own include iShares Preferred and Income Securities ETF (PFF) , Micron Technology (MU) , IVERIC bio (OPHT) , SentinelOne (S) , Starbucks (SBUX) , SunPower (SPWR) , Apollo Investment (AINV) , Argos Therapeutics (ARGSQ) , Broadcom (AVGO) and Bausch Health Companies (BHC) .

When did Dyne Therapeutics IPO?

(DYN) raised $175 million in an IPO on Thursday, September 17th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO.

Who are Dyne Therapeutics' major shareholders?

Dyne Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Braidwell LP (2.97%), Armistice Capital LLC (1.96%), Vivo Capital LLC (1.69%), FMR LLC (1.38%), Assenagon Asset Management S.A. (1.18%) and Northern Trust Corp (0.64%). Insiders that own company stock include Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Richard William Scalzo, Susanna Gatti High and Wildon Farwell. View institutional ownership trends .

How do I buy shares of Dyne Therapeutics?

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Dyne Therapeutics Stock Price, News & Analysis (NYSE:DYN)

$11.20

+0.12 (+1.08%)

(As of 12/1/2023 ET)

Compare

Today's Range: $10.36
▼
$11.30
50-Day Range: $6.62
▼
$11.20
52-Week Range: $6.40
▼
$15.60

Volume: 473,883 shs
Average Volume: 682,267 shs
Market Capitalization: $687.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.20

Dyne Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.20 Rating Score
Upside/Downside: 142.9% Upside
$27.20 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$145,621 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.73) to ($2.89) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

437th out of 957 stocks

Pharmaceutical Preparations Industry

197th out of 437 stocks

3.6

Analyst's Opinion

Consensus Rating
Dyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $27.20, Dyne Therapeutics has a forecasted upside of 142.9% from its current price of $11.20.
Amount of Analyst Coverage
Dyne Therapeutics has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for DYN.

0.0

Dividend Strength

Dividend Yield
Dyne Therapeutics does not currently pay a dividend.
Dividend Growth
Dyne Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DYN.

1.1

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Dyne Therapeutics this week, compared to 1 article on an average week.
Search Interest
4 people have searched for DYN on MarketBeat in the last 30 days.
MarketBeat Follows
3 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Dyne Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $145,621.00 in company stock.
Percentage Held by Insiders
32.89% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Dyne Therapeutics are expected to grow in the coming year, from ($3.73) to ($2.89) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Dyne Therapeutics is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Dyne Therapeutics is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Dyne Therapeutics has a P/B Ratio of 4.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Dyne Therapeutics Stock (NYSE:DYN)

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

DYN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DYN Stock News Headlines

December 1, 2023 | americanbankingnews.com

StockNews.com Upgrades Dyne Therapeutics (NYSE:DYN) to Sell

November 21, 2023 | finance.yahoo.com

3 of the Best Cheap Stocks Under $20 to Buy Now: November Edition

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 7, 2023 | finance.yahoo.com

Dyne Therapeutics to Present at November Investor Conferences

November 3, 2023 | benzinga.com

Dyne Therapeutics Chief Operating Officer Trades $73K In Company Stock

October 31, 2023 | morningstar.com

Dyne Therapeutics Inc Ordinary Shares

October 31, 2023 | finance.yahoo.com

Dyne Therapeutics Inc (DYN) Reports Q3 2023 Financial Results and Progress in Clinical Trials

October 31, 2023 | finance.yahoo.com

The Dyne Therapeutics Inc (DYN) Company: A Short SWOT Analysis

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

October 30, 2023 | msn.com

Dyne Therapeutics GAAP EPS of -$0.99 misses by $0.16

October 30, 2023 | finance.yahoo.com

Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones

October 24, 2023 | finance.yahoo.com

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

September 28, 2023 | finance.yahoo.com

Dyne Therapeutics to Present at October Investor Conferences

September 25, 2023 | benzinga.com

Myotonic Dystrophy Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)

September 22, 2023 | marketwatch.com

Dyne Therapeutics Gets New FDA Orphan Drug Designation

September 22, 2023 | markets.businessinsider.com

Dyne Therapeutics's DYNE-101 Gets Orphan Drug Designation From FDA

September 22, 2023 | msn.com

Dyne Therapeutics gets FDA orphan drug status for DM1 drug

September 20, 2023 | finance.yahoo.com

Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

September 18, 2023 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)

September 15, 2023 | finance.yahoo.com

Why Shares of Dyne Therapeutics Fell This Week

September 14, 2023 | finance.yahoo.com

Insider Sell: Chief Medical Officer Wildon Farwell Sells 1,707 Shares of Dyne Therapeutics Inc

September 10, 2023 | msn.com

Dyne Therapeutics: Muscle Disease Oligo Therapy Developer In Early Stages

September 5, 2023 | finance.yahoo.com

Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

August 24, 2023 | finance.yahoo.com

CARGO Therapeutics Appoints Biotech Life Sciences Leaders to Board of Directors

August 10, 2023 | msn.com

JP Morgan Maintains Dyne Therapeutics (DYN) Overweight Recommendation

August 3, 2023 | seekingalpha.com

Dyne Therapeutics GAAP EPS of -$1.08

August 3, 2023 | finance.yahoo.com

Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

See More Headlines

Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/30/2023
Today: 12/03/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/07/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:DYN
CUSIP: N/A
CIK: 1818794
Web: www.dyne-tx.com
Phone: 781-786-8230
Fax: 781-786-8866
Employees: 136
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $27.20
High Stock Price Target: $34.00
Low Stock Price Target: $20.00
Potential Upside/Downside: +142.9%
Consensus Rating: Buy
Rating Score (0-4): 3.20
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-168,100,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -97.57%
Return on Assets: -79.16%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.67
Quick Ratio: 5.67

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.48 per share
Price / Book: 4.52

Miscellaneous

Outstanding Shares: 61,380,000
Free Float: 41,189,000
Market Cap: $687.46 million
Optionable: Optionable
Beta: 0.78

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Joshua T. Brumm (Age 45)
CEO, President & Director
Comp: $946.5k
Ms. Susanna Gatti High M.B.A. (Age 55)
Chief Operating Officer
Comp: $655.5k
Dr. Oxana Beskrovnaya Ph.D. (Age 61)
Chief Scientific Officer
Comp: $631.08k
Dr. Romesh Subramanian Ph.D. (Age 58)
Co-Founder & Advisor
Comp: $565.17k
Mr. Richard William Scalzo M.B.A. (Age 36)
Senior VP and Head of Finance & Administration
Mr. John Najim M.B.A.
Chief Technical Officer
Ms. Amy Reilly (Age 49)
Senior VP and Head of Corporate Communications & Investor Relations
Mr. Daniel Wilson (Age 51)
Senior VP & Head of Legal
Ms. Kate Mitchell
VP & Head of Human Resources
Ms. Debra Feldman (Age 52)
Chief Regulatory Affairs Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DYN Stock Analysis - Frequently Asked Questions

Should I buy or sell Dyne Therapeutics stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares.
View DYN analyst ratings or view top-rated stocks.
What is Dyne Therapeutics' stock price target for 2024?: 5 equities research analysts have issued 1 year price objectives for Dyne Therapeutics' shares. Their DYN share price targets range from $20.00 to $34.00. On average, they predict the company's share price to reach $27.20 in the next twelve months. This suggests a possible upside of 142.9% from the stock's current price.
View analysts price targets for DYN or view top-rated stocks among Wall Street analysts.
How have DYN shares performed in 2023?: Dyne Therapeutics' stock was trading at $11.59 on January 1st, 2023. Since then, DYN stock has decreased by 3.4% and is now trading at $11.20.
View the best growth stocks for 2023 here.
When is Dyne Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our DYN earnings forecast.
How were Dyne Therapeutics' earnings last quarter?: Dyne Therapeutics, Inc. (NYSE:DYN) announced its quarterly earnings results on Monday, October, 30th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.83) by $0.16.
What ETFs hold Dyne Therapeutics' stock?: ETFs with the largest weight of Dyne Therapeutics (NYSE:DYN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Dyne Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Dyne Therapeutics investors own include iShares Preferred and Income Securities ETF (PFF), Micron Technology (MU), IVERIC bio (OPHT), SentinelOne (S), Starbucks (SBUX), SunPower (SPWR), Apollo Investment (AINV), Argos Therapeutics (ARGSQ), Broadcom (AVGO) and Bausch Health Companies (BHC).
When did Dyne Therapeutics IPO?: (DYN) raised $175 million in an IPO on Thursday, September 17th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO.
Who are Dyne Therapeutics' major shareholders?: Dyne Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Braidwell LP (2.97%), Armistice Capital LLC (1.96%), Vivo Capital LLC (1.69%), FMR LLC (1.38%), Assenagon Asset Management S.A. (1.18%) and Northern Trust Corp (0.64%). Insiders that own company stock include Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Richard William Scalzo, Susanna Gatti High and Wildon Farwell.
View institutional ownership trends.
How do I buy shares of Dyne Therapeutics?: Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:DYN) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Dyne Therapeutics Stock Price, News & Analysis (NYSE:DYN)

Dyne Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Dyne Therapeutics Stock (NYSE:DYN)

DYN Stock Price History

DYN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

DYN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™